🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
19/04/2018 70,10 73,50 70,10 71,00 +1,43% 4,85% 18.301
18/04/2018 70,00 70,50 69,00 70,00 +0,00% 2,14% 10.671
17/04/2018 68,80 70,40 67,80 70,00 +1,30% 3,78% 23.102
16/04/2018 68,30 69,50 67,70 69,10 +2,37% 2,64% 16.764
13/04/2018 69,20 69,50 66,60 67,50 -2,74% 4,19% 33.043
12/04/2018 65,90 70,60 65,60 69,40 +7,93% 7,59% 47.048
11/04/2018 64,90 66,20 63,90 64,30 +0,00% 3,54% 22.382
10/04/2018 66,00 67,00 63,90 64,30 +0,31% 4,70% 49.002
09/04/2018 61,30 64,70 61,00 64,10 +7,37% 6,04% 32.012
06/04/2018 61,00 62,00 59,60 59,70 -2,93% 3,93% 10.186
05/04/2018 62,00 63,20 60,70 61,50 +1,49% 4,03% 25.910
04/04/2018 63,00 63,20 58,50 60,60 -3,35% 7,46% 38.827
03/04/2018 63,00 64,40 61,80 62,70 -3,83% 4,13% 29.873
29/03/2018 63,00 65,50 62,50 65,20 +3,66% 4,76% 20.760
28/03/2018 63,30 63,50 62,00 62,90 -0,63% 2,37% 27.349
27/03/2018 65,50 65,50 63,30 63,30 -0,94% 3,36% 9.024
26/03/2018 67,50 67,80 63,50 63,90 -1,54% 6,37% 18.374
23/03/2018 65,00 66,20 64,00 64,90 -1,96% 3,38% 15.079
22/03/2018 67,00 67,50 64,40 66,20 +0,91% 4,63% 24.072
21/03/2018 66,20 66,80 65,20 65,60 +0,00% 2,42% 10.307
20/03/2018 65,50 66,90 65,10 65,60 +1,23% 2,75% 12.192
19/03/2018 66,10 66,30 64,30 64,80 -0,46% 3,03% 15.432
16/03/2018 68,90 69,00 65,10 65,10 -4,12% 5,66% 21.592
15/03/2018 69,30 69,80 67,80 67,90 -2,02% 2,89% 13.687
14/03/2018 65,70 69,50 65,40 69,30 +6,78% 6,24% 45.257
13/03/2018 64,30 67,00 64,00 64,90 +0,93% 4,67% 30.712
12/03/2018 64,60 65,40 63,70 64,30 +0,63% 2,63% 18.786
09/03/2018 64,50 64,80 62,60 63,90 -0,47% 3,41% 43.671
08/03/2018 63,40 65,80 63,30 64,20 +1,10% 3,94% 33.099
07/03/2018 65,50 66,00 63,50 63,50 -3,50% 3,82% 17.656